Trastuzumab: new indication. Adjuvant breast cancer treatment for a minority.
An improvement in survival time, but cardiotoxicity remains a concern.
D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics / Q000401:mortality; D017024:Chemotherapy, Adjuvant; D005260:Female; D005602:France; D006801:Humans; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000235:genetics
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D018719:Erb-b2 Receptor Tyrosine Kinases